National Institute on Drug Abuse; Notice of Closed Meetings, 1699-1700 [E9-280]

Download as PDF Federal Register / Vol. 74, No. 8 / Tuesday, January 13, 2009 / Notices Dated: January 6, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–417 Filed 1–12–09; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Center for Research Resources; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Research Resources Council. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Research Resources Council. Date: February 12, 2009. Open: 8 a.m. to 11:55 a.m. Agenda: Report of the Director, NCRR and other Council business. Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892. Closed: 1 p.m. to 4 p.m. Agenda: To review and evaluate grant applications and/or proposals. Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892. Contact Person: Louise E. Ramm, PhD, Deputy Director, National Center for Research Resources, National Institutes of Health, Building 31, Room 3B11, Bethesda, MD 20892, 301–496–6023, louiser@ncrr.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when VerDate Nov<24>2008 19:10 Jan 12, 2009 Jkt 217001 applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs and hotel and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: https:// www.ncrr.nih.gov/newspub/minutes.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research; 93.371, Biomedical Technology; 93.389, Research Infrastructure; 93.306, 93.333, National Institutes of Health, HHS) Dated: January 6, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–426 Filed 1–12–09; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse; Special Emphasis Panel CEBRA Review. Date: January 16, 2009. Time: 1 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Mark Swieter, PhD, Chief, Training and Special Projects Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse. NIH, DHHS, 6101 PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 1699 Executive Boulevard, Suite 220, Bethesda, MD 20892–8401, (301) 435–1389, ms80x@nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute on Drug Abuse; Special Emphasis Panel; Medications Development for CannabisRelated Disorders. Date: January 29, 2009. Time: 8:30 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015. Contact Person: Meenaxi Hiremath, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6101 Executive Blvd., Suite 220, MSC 8401, Bethesda, MD 20892, 301–402–7964, mh392g@nih.gov. Name of Committee: National Institute on Drug Abuse; Special Emphasis Panel; Pilot Clinical Trials of Pharmacotherapies for Substance Related. Date: February 9, 2009. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Sofitel Hotel, 806 15th Street, NW., Washington, DC 20005. Contact Person: Eliane Lazar-Wesley, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda. MD 20892–8401, 301–451–4530, elazarwe@nida.nih.gov. Name of Committee: National Institute on Drug Abuse, Initial Review Group, Health Services Research Subcommittee, NIDA–F. Date: February 10–11, 2009. Time: 8:30 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Melrose Hotel, 2430 Pennsylvania Ave., NW., Washington, DC 20037. Contact Person: Meenaxi Hiremath, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6101 Executive Blvd., Suite 220, MSC 8401, Bethesda, MD 20892, 301–402–7964, mh392g@nih.gov. Name of Committee: National Institute on Drug Abuse, Special Emphasis Panel,NIDA– F Conflicts. Date: February 10, 2009. Time: 3 p.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Melrose Hotel, 2430 Pennsylvania Ave., NW., Washington, DC 20037. Contact Person: Gerald L. McLaughlin, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., Bethesda, MD 20892–8401, 301–402–6626, gm145a@nih.gov. E:\FR\FM\13JAN1.SGM 13JAN1 1700 Federal Register / Vol. 74, No. 8 / Tuesday, January 13, 2009 / Notices Name of Committee: National Institute on Drug Abuse, Special Emphasis Panel, NIDA– E Conflicts. Date: February 11, 2009. Time: 9 a.m. to 12 p.m. Agenda: To review and evaluate grant applications. Place: Melrose Hotel, 2430 Pennsylvania Ave., NW., Washington, DC 20037. Contact Person: Eliane Lazar-Wesley, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892–8401, 301–451–4530, elazarwe@nida.nih.gov. Name of Committee: National Institute on Drug Abuse; Initial Review Group; Medication Development Research Subcommittee. Date: February 12, 2009. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications Place: Double Tree Hotel, 1515 Rhode Island Avenue, NW., Washington, DC 20005. Contact Person: Jose F Ruiz, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6101 Executive Blvd., Rm. 213, MSC 8401, Bethesda, MD 20892, 301–451–3086, ruizjf@nida.nih.gov. Name of Committee: National Institute on Drug Abuse; Initial Review Group Training and; Career Development Subcommittee. Date: March 17–18, 2009. Time: 8:30 a.m. to 5:30 p.m. Agenda: To review and evaluate grant applications. Place: Ritz Carlton Hotel, 1150 22nd Street, NW., Washington, DC 20037. Contact Person: Eliane Lazar-Wesley, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6101 Executive Boulevard, Room 220, MSC 8401, Bethesda, MD 20892–8401, 301–451–4530, el6r@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: January 5, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–280 Filed 1–12–09; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of meetings of the VerDate Nov<24>2008 19:10 Jan 12, 2009 Jkt 217001 National Diabetes and Digestive and Kidney Diseases Advisory Council. The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Diabetes and Digestive and Kidney Diseases Advisory Council. Date: February 18, 2009. Open: 8:30 a.m. to 11:45 a.m. Agenda: To present the Director’s Report and other scientific Presentations. Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892. Closed: 4:10 p.m. to 4:40 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892. Contact Person: Brent B. Stanfield, PhD, Director, Division of Extramural Activities, National Institutes of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Blvd., Room 715, MSC 5452, Bethesda, MD 20892, (301) 594–8843, stanfibr@niddk.nih.gov. Name of Committee: National Diabetes and Digestive and Kidney Diseases, Advisory Council, Diabetes, Endocrinology, and Metabolic Diseases Subcommittee. Date: February 18, 2009. Open: 1 p.m. to 2:30 p.m. Agenda: To review the Division’s scientific and planning activities. Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892. Closed: 2:30 p.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892. Contact Person: Brent B. Stanfield, PhD, Director, Division of Extramural Activities, National Institutes of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Blvd., Room 715, MSC 5452, Bethesda, MD 20892, (301) 594–8843, stanfibr@niddk.nih.gov. Name of Committee: National Diabetes and Digestive and Kidney Diseases, Advisory Council, Digestive Diseases and Nutrition Subcommittee. PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 Date: February 18, 2009. Open: 1 p.m. to 2:30 p.m. Agenda: To review the Division’s scientific and planning activities. Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 6, Bethesda, MD 20892. Closed: 2:30 p.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 6, Bethesda, MD 20892. Contact Person: Brent B. Stanfield, PhD, Director, Division Of Extramural Activities, National Institutes of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Blvd., Room 715, MSC 5452, Bethesda, MD 20892, (301) 594–8843, stanfibr@niddk.nih.gov. Name of Committee: National Diabetes and Digestive and Kidney Diseases, Advisory Council, Kidney, Urologic, and Hematologic Diseases Subcommittee. Date: February 18, 2009. Open: 1 p.m. to 2:30 p.m. Agenda: To review the Division’s scientific and planning activities. Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 7, Bethesda, MD 20892. Closed: 2:30 p.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 7, Bethesda, MD 20892. Contact Person: Brent B. Stanfield, PhD, Director, Division of Extramural Activities, National Institutes of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Blvd. Room 715, MSC 5452, Bethesda, MD 20892, (301) 594–8843, stanfibr@niddk.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institutes/Center’s home page: https:// www.niddk.nih.gov/fund/divisions/DEA/ Council/coundesc.htm., where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS) E:\FR\FM\13JAN1.SGM 13JAN1

Agencies

[Federal Register Volume 74, Number 8 (Tuesday, January 13, 2009)]
[Notices]
[Pages 1699-1700]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-280]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse; Special 
Emphasis Panel CEBRA Review.
    Date: January 16, 2009.
    Time: 1 p.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6101 Executive Boulevard, 
Rockville, MD 20852 (Virtual Meeting).
    Contact Person: Mark Swieter, PhD, Chief, Training and Special 
Projects Review Branch, Office of Extramural Affairs, National 
Institute on Drug Abuse. NIH, DHHS, 6101 Executive Boulevard, Suite 
220, Bethesda, MD 20892-8401, (301) 435-1389, ms80x@nih.gov.

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

    Name of Committee: National Institute on Drug Abuse; Special 
Emphasis Panel; Medications Development for Cannabis-Related 
Disorders.
    Date: January 29, 2009.
    Time: 8:30 a.m. to 6 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military 
Road, NW., Washington, DC 20015.
    Contact Person: Meenaxi Hiremath, PhD, Health Scientist 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, National Institutes of Health, DHHS, 6101 Executive 
Blvd., Suite 220, MSC 8401, Bethesda, MD 20892, 301-402-7964, 
mh392g@nih.gov.

    Name of Committee: National Institute on Drug Abuse; Special 
Emphasis Panel; Pilot Clinical Trials of Pharmacotherapies for 
Substance Related.
    Date: February 9, 2009.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Sofitel Hotel, 806 15th Street, NW., Washington, DC 
20005.
    Contact Person: Eliane Lazar-Wesley, PhD, Health Scientist 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, 
Bethesda. MD 20892-8401, 301-451-4530, elazarwe@nida.nih.gov.

    Name of Committee: National Institute on Drug Abuse, Initial 
Review Group, Health Services Research Subcommittee, NIDA-F.
    Date: February 10-11, 2009.
    Time: 8:30 a.m. to 6 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Melrose Hotel, 2430 Pennsylvania Ave., NW., Washington, 
DC 20037.
    Contact Person: Meenaxi Hiremath, PhD, Health Scientist 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, National Institutes of Health, DHHS, 6101 Executive 
Blvd., Suite 220, MSC 8401, Bethesda, MD 20892, 301-402-7964, 
mh392g@nih.gov.
    Name of Committee: National Institute on Drug Abuse, Special 
Emphasis Panel,NIDA-F Conflicts.
    Date: February 10, 2009.
    Time: 3 p.m. to 6 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Melrose Hotel, 2430 Pennsylvania Ave., NW., Washington, 
DC 20037.
    Contact Person: Gerald L. McLaughlin, PhD, Scientific Review 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., 
Bethesda, MD 20892-8401, 301-402-6626, gm145a@nih.gov.


[[Page 1700]]


    Name of Committee: National Institute on Drug Abuse, Special 
Emphasis Panel, NIDA-E Conflicts.
    Date: February 11, 2009.
    Time: 9 a.m. to 12 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Melrose Hotel, 2430 Pennsylvania Ave., NW., Washington, 
DC 20037.
    Contact Person: Eliane Lazar-Wesley, PhD, Health Scientist 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, 
Bethesda, MD 20892-8401, 301-451-4530, elazarwe@nida.nih.gov.

    Name of Committee: National Institute on Drug Abuse; Initial 
Review Group; Medication Development Research Subcommittee.
    Date: February 12, 2009.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications
    Place: Double Tree Hotel, 1515 Rhode Island Avenue, NW., 
Washington, DC 20005.
    Contact Person: Jose F Ruiz, PhD, Scientific Review 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, 6101 Executive Blvd., Rm. 213, MSC 8401, 
Bethesda, MD 20892, 301-451-3086, ruizjf@nida.nih.gov.

    Name of Committee: National Institute on Drug Abuse; Initial 
Review Group Training and; Career Development Subcommittee.
    Date: March 17-18, 2009.
    Time: 8:30 a.m. to 5:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Ritz Carlton Hotel, 1150 22nd Street, NW., Washington, DC 
20037.
    Contact Person: Eliane Lazar-Wesley, PhD, Health Scientist 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, 6101 Executive Boulevard, Room 220, MSC 8401, 
Bethesda, MD 20892-8401, 301-451-4530, el6r@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: January 5, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-280 Filed 1-12-09; 8:45 am]
BILLING CODE 4140-01-M
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.